Skip to main content
. 2010 May;5(4):69–89.

TABLE 5.

Perceived effects of physician–pharmaceutical industry interactions

Percentage of respondents that perceive effects on the cost of healthcare
Increase cost (%) No effect (%) Decrease cost (%) Unsure (%)
Gifts overall 334, 54.59, 642 231, 394, 10.39 3.11 284, 35.29
Office gifts 262 382 192 162
Personal gifts 422 302 142 142
Percentage of respondents that perceive effects on quality of healthcare
Negative effect (%) No effect (%) Positive effect (%) Unsure (%)
Office gifts 132 612 142 122
Personal gifts 232 542 82 152
Very worried (%) Somewhat worried (%) A little worried (%) Not worried at all (%)
Financial interactions <18 68 118 808
Percentage of respondents that perceive effects on prescribing practices
Influence (%) Little/No influence (%) Unsure (%)
Gifts overall 236, 29.19, 361, 701 24.51
Small gifts – pen 8.69, 314 76.69 14.89
Small gifts – pocket knife 284
Small gifts – mug 314
Large gifts – medical device 54.8, 68.39 10.9, 25.99 19.3, 20.89
Large gifts – car seat cover 35.39 46.19 18.69
CME – medical text 21.69, 384, 374 57.79 20.79
CME – video 384
CME – conference expenses 37.8, 51.29 21.2, 32.49 27.6, 29.89
Drug sample 424
Meals – lunch 294
Meals – dinner 484, 38.59 37.69 22.99
Travel 564, 64.29 12.59 23.39
Percentage of respondents that would be inclined to participate in a research study following disclosure of physician–pharmaceutical interactions
Less inclined (%) Depends on amount (%) Same as before (%) More inclined (%)
Personal income 22, 31, 287 8, 13, 117 53, 46, 507 16, 10, 117
Researcher patent 26, 23, 317 - 62, 67, 607 12, 11, 97
Researcher stocks 37, 36, 407 - 55, 59, 547 8, 5, 67
Per capita payment 16, 23, 177 - 68, 65, 707 17, 12, 137
Percentage of respondents that would participate in a clinical trial following disclosure of physician–pharmaceutical interactions
Stop participation (%) No effect on participation (%) Encourage participation (%) Other (%)
Patent royalties 148 708 78 98
Percentage of respondents that would participate in a clinical trial following disclosure of physician–pharmaceutical interactions
Stop participation (%) No effect on participation (%) Encourage participation (%) Other (%)
Stock ownership 118 768 18 118
Consulting 128 758 68 78
Speaking fees 98 828 48 68
Would not participate (%) Depends on amount (%) Still consider participation (%) Unsure (%)
Personal income 12, 18, 187 9, 14, 127 79, 67, 707
Researcher patent 13, 11, 177 75, 72, 687 12, 17, 147
Researcher stocks 17, 14, 207 65, 61, 597 18, 26, 217
Per capita payment 7, 11, 97 83, 74, 807 10, 15, 117
Percentage of respondents that believe financial interactions influence a physician to enrol patients in a clinical trial
Influence (%) No Influence (%)
Per-patient payments 698 -
1

Blake and Early, 1995 (self-administered survey, n=486);

2

Mainous et al. 1995 (telephone survey, n=649);

3

LaPuma et al. 1995 (self-administered survey, n=200);

4

Gibbons et al. 1998 (face-to-face survey, n=196);

5

Eaton 2003 (online poll, n=1,479);

6

Wall Street Journal Online 2003 (online poll, n=4,173);

7

Kim et al. 2004 (Internet-administered survey, n=5,478);

8

Hampson et al. 2006 (face-to-face survey, n=253);

9

Semin et al. 2006 (face-to-face survey, n=253);

10

Weinfurt et al. 2006 (focus group, n=139).

Results reported as coronary artery disease group (n=2,355), breast cancer group (n=1,006), depression group (n=2,117), respectively CME = continuing medical education